However, specific knockdown of HSF1 and the administration of the SYK inhibitor R406 can reverse the potentiating effect of 125I radiotherapy on the ROS/USP7/P53 pathway, consequently promoting the progression of cervical cancer; specific overexpression of PU.1 can abrogate the inhibitory impact of HSF1 knockdown on the ROS/USP7/P53 pathway, thereby suppressing the progression of cervical cancer. Here, USP7 is linked to cervical carcinoma.